A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)
Active Idiopathic Inflammatory Myopathy
About this trial
This is an interventional treatment trial for Active Idiopathic Inflammatory Myopathy
Eligibility Criteria
Inclusion Criteria:
- Ability to consent in the jurisdiction in which the study is taking place and capable of giving signed informed consent.
- A definite or probable clinical diagnosis of idiopathic inflammatory myopathy (IIM)
One of the following medical histories:
- Diagnosis of dermatomyositis (DM) or juvenile dermatomyositis (JDM), (age of disease onset <18 years of age). The diagnosis date for juvenile dermatomyositis should not be >5 years from the screening date.
- Diagnosis of polymyositis (PM) (including antisynthetase syndrome (ASyS))
- Diagnosis of immune-mediated necrotizing myopathy (IMNM)
Diagnosed with active disease as defined by the presence of at least 1 of the following criteria:
- Abnormal levels of at least 1 of the following enzymes: creatine kinase (CK), aldolase, lactate dehydrogenase, aspartate aminotransaminase (AST), alanine aminotransferase (ALT), based on central laboratory results
- Electromyography demonstrating active disease within the past 3 months
- Active dermatomyositis (DM) skin rash
- Muscle biopsy indicative of active idiopathic inflammatory myopathy (IIM) in the past 3 months
- Magnetic resonance imaging within the past 3 months indicative of active inflammation
- Muscle weakness
- Receiving a permitted background treatment for idiopathic inflammatory myopathy.
- Contraceptive use by nonsterilized male participants and women of childbearing potential will be consistent with local regulations, where available, for individuals participating in clinical studies. Women of childbearing potential must have a negative serum pregnancy test during screening and a negative urine pregnancy test at baseline to establish the nonpregnant state before receiving investigational medicinal product (IMP).
The full list of inclusion criteria can be found in the protocol.
Exclusion Criteria:
- A clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection at screening
- A COVID-19 polymerase chain reaction (PCR)-positive test before enrollment
- Any other known autoimmune disease that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of idiopathic inflammatory myopathy (IIM) or put the patient at undue risk
A history of malignancy unless considered cured by adequate treatment, with no evidence of recurrence for ≥ 3 years before the first administration of the investigational medicinal product (IMP). Adequately treated participants with the following cancers can be included at any time:
- Basal cell or squamous cell skin cancer
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast
- Incidental histological finding of prostate cancer
- Severe muscle damage
- Glucocorticoid-induced myopathy that the investigator considers the primary cause of muscle weakness or permanent weakness linked to a non-idiopathic inflammatory myopathy (IIM) cause
- Juvenile myositis (JDM) diagnosed > 5 years from screening or juvenile myositis with extensive calcinosis or severe calcinosis.
- Uncontrolled interstitial lung disease or any other uncontrolled idiopathic inflammatory myopathy (IIM) manifestation that, in the opinion of the investigator, would be likely to require treatment with prohibited medication during the study
- Other inflammatory and noninflammatory myopathies: inclusion body myositis, overlap myositis), metabolic myopathies, muscle dystrophies or a family history of muscle dystrophy, drug-induced or endocrine induced myositis, and juvenile myositis (other than juvenile dermatomyositis (JDM))
- Clinically significant disease, recent major surgery or intends to have surgery during the study, or has any other condition in the opinion of the investigator that could confound the results of the trial or put the patient at undue risk
- Known hypersensitivity reaction to investigational medicinal product (IMP) or 1 of its excipients
- Received a live or live-attenuated vaccine less than 4 weeks before screening.
- Lack of clinical response to plasmapheresis/plasma exchange (PLEX)
Positive serum test at screening for active viral infection with any of the following conditions:
- Hepatitis B virus (HBV)
- Hepatitis C virus (HCV)
- HIV
Any of the following prior therapy or procedures:
- Treatment within 2 weeks before screening: topical corticosteroids or topical immunomodulators (eg, tacrolimus) for idiopathic inflammatory myopathy (IIM) rash
- Treatment within 4 weeks before screening: local corticosteroid injections, anakinra, etanercept, Janus kinase (JAK) inhibitors, corticosteroids, plasmapheresis/plasma exchange, immunoadsorption
- Treatment within 8 weeks before screening: corticosteroid precursors
- Treatment within 12 weeks before screening: IVIg, SCIg, tocilizumab, abatacept, infliximab, adalimumab, golimumab, certolizumab, ustekinumab
- Treatment within 24 weeks before screening: rituximab or other anti-CD20 antibody, cyclophosphamide
- Use of a nonbiologic investigational product within 12 weeks before screening
- Use of a biologic therapy and/or monoclonal antibody within 24 weeks before screening
- Treatment with oral corticosteroids
- Treatment with >1 immunosuppressant, >1 antimalarial, or a combination of an immunosuppressant and an antimalarial
- Participant has previously participated in an efgartigimod clinical trial and received at least 1 dose of investigational medicinal product (IMP).
- Participant is concurrently participating in any other clinical study, including a noninterventional study.
- Participant has a current or history (ie, within 12 months of screening) of alcohol, drug, or medication abuse.
- Participant is pregnant or lactating or intends to become pregnant during the study.
- Participant has severe renal impairment .
- Participant is institutionalized by a court or other governmental order or is in a dependent relationship with the sponsor or investigator.
The full list of exclusion criteria can be found in the protocol.
Sites / Locations
- Investigator site US0010122Recruiting
- Investigator site US0010013Recruiting
- Investigator site US0010127Recruiting
- Investigator site US0010004Recruiting
- Investigator site US0010092Recruiting
- Investigator site US0010071Recruiting
- Investigator site US0010180Recruiting
- Investigator site US0010006Recruiting
- Investigator site US0010194Recruiting
- Sabine CoppietersRecruiting
- Investigator site US0010016Recruiting
- Investigator site US0010203Recruiting
- Investigator site US0010139Recruiting
- Investigator site US0010163Recruiting
- Investigator site US0010162Recruiting
- Investigator site US0010128Recruiting
- Investigator site US0010165Recruiting
- Investigator site US0010185Recruiting
- Investigator site US0010167Recruiting
- Investigator Site US0010170Recruiting
- Investigator Site US0010161Recruiting
- Investigator site US0010164Recruiting
- Investigator site US0010020Recruiting
- Investigator site AR0540005Recruiting
- Investigator site AR0540010Recruiting
- Investigator site AR0540006Recruiting
- Investigator site AR0540008Recruiting
- Investigator site AU0610015Recruiting
- Investigator site AU0610014Recruiting
- Investigator site AT0430011Recruiting
- Investigator site BE0320001Recruiting
- Investigator site BE0320009Recruiting
- Investigator site BE0320026Recruiting
- Investigator site BE0320023Recruiting
- Investigator site BG3590019Recruiting
- Investigator site BG3590021Recruiting
- Investigator site CA0019010Recruiting
- Investigator site CA0019008Recruiting
- Investigator site CY3570001Recruiting
- Investigator site DK0450007Recruiting
- Investigator site FR0330031Recruiting
- Investigator site FR0330043Recruiting
- Investigator site FR0330036Recruiting
- Investigator site GE9950026Recruiting
- Investigator site GE9950023Recruiting
- Investigator site GE9950024Recruiting
- Investigator site GE9950025Recruiting
- Investigator site GE9950027Recruiting
- Investigator site GE9950022Recruiting
- Investigator site DE0490038Recruiting
- Investigator site DE0490049Recruiting
- Investigator site DE0490043Recruiting
- Investigator site GR0300011Recruiting
- Investigator site GR0300014Recruiting
- Investigator site GR0300012Recruiting
- Investigator site GR0300015Recruiting
- Investigator site HU0360013Recruiting
- Investigator site HU0360021Recruiting
- Investigator site IE3530006Recruiting
- Investigator site IT0390049Recruiting
- Investigator site IT0390051Recruiting
- Investigator site IT0390050Recruiting
- Investigator site IT0390054Recruiting
- Investigator site IT0390064Recruiting
- Investigator site IT0390002Recruiting
- Investigator site KO0820012Recruiting
- Investigator site KO0820011Recruiting
- Investigator site KR0820009Recruiting
- Investigator site KR0820010Recruiting
- Investigator site KO0820013Recruiting
- Investigator site KR0820014Recruiting
- Investigator site LT3700001Recruiting
- Investigator site LT370002Recruiting
- Investigator site MX0520009Recruiting
- Investigator site NL0310010Recruiting
- Investigator site NL0310012Recruiting
- Investigator site PL0480042Recruiting
- Investigator site PL0480044Recruiting
- Investigator site PT3510008Recruiting
- Investigator site ES0340047Recruiting
- Investigator site ES0340048Recruiting
- Investigator site ES0340060Recruiting
- Investigator site ES0340049Recruiting
- Investigator site ES0340042Recruiting
- Investigator site ES0340039Recruiting
- Investigator site ES0340046Recruiting
- Investigator site SE0460002Recruiting
- Investigator site CH0410005Recruiting
- Investigator site TW8860009Recruiting
- Investigator site TW8860005Recruiting
- Investigator site TH0660014Recruiting
- Investigator site TH0660013Recruiting
- Investigator site TH0660015Recruiting
- Investigator site TH0660011Recruiting
- Investigator site TH0660016Recruiting
- Investigator site TH0660012Recruiting
- Investigator site TR0900027Recruiting
- Investigator site TR0900028Recruiting
- Investigator site TR0900029Recruiting
- Investigator site UK0440029Recruiting
- Investigator site UK0440038Recruiting
- Investigator site UK0440032Recruiting
- Investigator site UK0440025Recruiting
- Investigator site UK0440040Recruiting
- Investigator site UK0440023Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
EFG PH20 SC
PBO PH20 SC
participants receiving efgartigimod PH20 SC on top of background treatment
participants receiving placebo PH20 SC on top of background treatment